Population Pharmacokinetics of Golimumab, an Anti-Tumor Necrosis Factor-I plus or minus Human Monoclonal Antibody, in Patients With Psoriatic Arthritis

The population pharmacokinetics of subcutaneously administered golimumab (50 mg or 100 mg every 4 weeks) were characterized in patients with active psoriatic arthritis (PsA) in GO-REVEAL, a randomized, double-blind, placebo-controlled, phase 3 study. A total of 2029 serum golimumab concentrations fr...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical pharmacology 2009-09, Vol.49 (9), p.1056-1070
Hauptverfasser:	Vu, Thuy, Lee, Howard, Baker, Daniel, Beutler, Anna, Pendley, Charles, Wagner, Carrie, Davis, Hugh M
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!